Theravance Biopharma
901 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.theravance.com/
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIVĀ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
243 articles about Theravance Biopharma
-
Theravance Biopharma to Participate in an Upcoming September 2023 Investor Conference
8/29/2023
Theravance Biopharma, Inc. will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12 at 9:30 am ET and will be hosting in-person meetings with the investment community at the conference.
-
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
8/28/2023
Theravance Biopharma, Inc. announced new ampreloxetine data in neurogenic orthostatic hypotension will be presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders, taking place August 27-31, 2023, in Copenhagen, Denmark.
-
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
8/7/2023
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the second quarter of 2023.
-
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
7/24/2023
Theravance Biopharma, Inc. will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023.
-
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
5/9/2023
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) status to ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
-
Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
5/8/2023
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2023.
-
Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
4/24/2023
Theravance Biopharma, Inc. will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023.
-
Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
4/11/2023
Theravance Biopharma, Inc. announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors.
-
Theravance Biopharma to Participate in an Upcoming April 2023 Investor Conference
4/10/2023
Theravance Biopharma, Inc. will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET.
-
Theravance Biopharma is discontinuing research activities for its JAK inhibitor program in lung inflammation and reducing its headcount by about 17%.
-
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update
2/27/2023
Theravance Biopharma, Inc. announced financial results for the fourth quarter and full year ended December 31, 2022.
-
Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
2/21/2023
Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023.
-
Theravance Biopharma to Participate in an Upcoming February 2023 Investor Conference
2/9/2023
Theravance Biopharma, Inc. will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 8:00 am ET.
-
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets
1/9/2023
Theravance Biopharma, Inc. announced its 2022 Accomplishments and 2023 Key Targets.
-
Theravance Biopharma, Inc. Announces Final Results of Tender Offer
11/22/2022
Theravance Biopharma, Inc. announced the final results of its Dutch auction tender offer to purchase up to $95 million of its ordinary shares, par value $0.00001 per share, which expired at midnight, New York City time, at the end of the day on November 17, 2022.
-
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer
11/7/2022
Theravance Biopharma, Inc. reported financial results for the third quarter of 2022.
-
Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System
11/2/2022
Theravance Biopharma, Inc.Ā ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data in neurogenic orthostatic hypotension (nOH) from the Company's Phase 3 program at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society (AAS).
-
Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022
10/31/2022
Theravance Biopharma, Inc. will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022.
-
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
10/25/2022
Theravance Biopharma, Inc. announced new ampreloxetine data in neurogenic orthostatic hypotension will be presented at the 33rd International Symposium on the Autonomic Nervous System, a meeting of the American Autonomic Society, taking place November 2-5, 2022, in Maui, Hawaii.
-
Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
9/28/2022
Theravance Biopharma, Inc. announced a "modified Dutch auction" tender offer to purchase up to $95 million of its ordinary shares, par value $0.00001 per share.